Sanam Loghavi, MD

Experts explain who benefits from menin inhibitors in AML, which tests to order at relapse, and how to choose revumenib vs ziftomenib.

Experts explain how menin inhibitors target KMT2A and NPM1 AML, why retesting matters, and how to choose approved drugs or trials.

In community settings, offices may have to send pathology specimens to reference labs, and it may be difficult to maintain effective communication.

Morphological dysplasia is the cornerstone of making a myelodysplastic syndrome diagnosis, except for a few myelodysplastic syndrome–defining genetic alterations.